Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J E Janik

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignanciesJ W Smith, W J Urba, B D Curti, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|March 1, 1996
Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancerB D Curti, W J Urba, D L Longo, et al.
Blood|March 27, 2001
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinomaJ E Janik, L L Miller, E L Korn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancerB L Gause, M Sznol, W C Kopp, et al.
Clinical Immunology (Orlando, Fla.)|December 22, 1999
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patientsJ E Janik, L L Miller, W C Kopp, et al.
Cancer Journal (Sudbury, Mass.)|July 6, 2000
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II studyD L Longo, P L Duffey, J G Gribben, et al.
Blood|May 11, 1999
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatinL L Miller, E L Korn, D S Stevens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancerB D Curti, A C Ochoa, G C Powers, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patientsB D Curti, A C Ochoa, W J Urba, et al.
Journal of the National Cancer Institute|January 3, 1996
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanomaJ E Janik, L L Miller, D L Longo, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignanciesJ W Smith, W J Urba, B D Curti, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|March 1, 1996
Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancerB D Curti, W J Urba, D L Longo, et al.
Blood|March 27, 2001
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinomaJ E Janik, L L Miller, E L Korn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1996
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancerB L Gause, M Sznol, W C Kopp, et al.
Clinical Immunology (Orlando, Fla.)|December 22, 1999
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patientsJ E Janik, L L Miller, W C Kopp, et al.
Cancer Journal (Sudbury, Mass.)|July 6, 2000
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II studyD L Longo, P L Duffey, J G Gribben, et al.
Blood|May 11, 1999
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatinL L Miller, E L Korn, D S Stevens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancerB D Curti, A C Ochoa, G C Powers, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patientsB D Curti, A C Ochoa, W J Urba, et al.
Journal of the National Cancer Institute|January 3, 1996
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanomaJ E Janik, L L Miller, D L Longo, et al.
Pageof 4